2026-01-23 - Analysis Report
**Company Overview:**
Abbott Labs is a multinational health care company that operates in four business segments: Established Pharmaceuticals, Nutritionals, Diagnostics, and Vascular.

**Return Rate Comparison:**
- Ticker to review: ABT (Abbott Labs)
- Cumulative return of review stock: 18.23%
- Cumulative return of comparison stock (S&P 500, VOO): 92.53%
- Divergence: -60.80 (-37.10 ~ -60.80 min range)

**Analysis:**
The cumulative return of Abbott Labs is significantly lower than the S&P 500 index. This indicates that the stock has performed poorly compared to the broader market.

**Alpha, Beta Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 32.0% | 14.5% | 28.0% | 1.1 | 125.9B |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0 | 151.2B |
| 2018-2020  | -1.0% | 16.8% | -22.0% | 0.9 | 190.6B |
| 2019-2021  | 42.0% | 16.8% | -2.0% | 0.8 | 244.9B |
| 2020-2022  | -20.0% | 28.8% | -18.0% | 0.8 | 191.1B |
| 2021-2023  | -22.0% | 28.8% | -23.0% | 0.7 | 191.6B |
| 2022-2024  | -31.0% | 24.3% | -50.0% | 0.7 | 196.9B |
| 2023-2025  | 10.0% | 16.0% | -52.0% | 0.3 | 218.1B |

**Analysis:**
The company's CAGR (Cumulative Annual Growth Rate) and Alpha (return difference) have been volatile over the years, with a downward trend in recent years. Beta (sensitivity to market changes) has remained relatively stable.

**Recent Stock Price Fluctuations:**
- Close: $108.61
- 5-day SMA: $119.15
- 20-day SMA: $123.86
- 60-day SMA: $125.40
- Last-market: {'price': 108.61, 'previousClose': 120.73, 'change': -10.04}

**Analysis:**
The stock price has been moving downward, with a significant decline in the last market session. The 5-day, 20-day, and 60-day SMAs indicate a downward trend.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**
- Market Risk Indicator (MRI): 0.90
- RSI: 16.98
- PPO: -1.06
- Hybrid Signal: Buy (Cash 0%)
- Recent (20 days) relative divergence change: -2.00 (-): worsening
- 7-day Rank change: 50 (+): rank up
- 7-day Dynamic Expected Return change: 0.80 (+): improving
- Expected Return (%): -1605.30%
If {'price': 108.61, 'previousClose': 120.73, 'change': -10.04} is large, reflect the fluctuation issue (sharp rebound, sharp decline).

**Analysis:**
The RSI and PPO indicators suggest a strongly bearish market sentiment. The company's expected return has dropped significantly.

**Recent News & Significant Events:**
- Abbott Dives 7% On Quarterly Upset As Exact Close Looms - Investor's Business Daily (news.google.com)
- Abbott posts Q4 topline miss as Nutrition unit contracts (ABT) - Seeking Alpha (news.google.com)
- ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth - TipRanks (news.google.com)
- Why Abbott Laboratories (ABT) Shares Are Sliding Today - Yahoo Finance (news.google.com)
- Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings. - Barron's (news.google.com)
- Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints - Benzinga (news.google.com)

**Analysis:**
The company has faced significant challenges, including a decline in the Nutrition business unit, leading to a lower-than-expected quarterly performance.

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): 144.75 / 169.00 / 122.00

**Analysis:**
The majority of analysts have a buy rating, with a target price above the current stock price.

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|-----|---:|---:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2025-10-29 | 0.94 | 10.63 B$ |

**Analysis:**
The company's earnings per share have been volatile, with a decline in the latest quarter. Revenue has been relatively consistent.

**Financial Information: Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

**Analysis:**
The company's revenue has been stable, with a slight decline in the latest quarter. Profit margin has been consistent.

**Financial Information: Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

**Analysis:**
The company's equity has been increasing, with a slight decline in the latest quarter. Return on Equity (ROE) has been volatile.

**Comprehensive Analysis:**
The company's financial performance has been challenging in recent years, with a decline in earnings and revenue. The stock price has also declined significantly. The company's expected return has dropped, and the analyst consensus is mixed, with a slight leaning towards buy.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.